Publications by authors named "Fatemeh Nobahari"
Article Synopsis
- The study investigated the safety, efficacy, and immune response to the Sinopharm BBIBP-CorV vaccine in people with multiple sclerosis (PwMS) receiving various disease-modifying therapies (DMTs).
- Out of 261 screened PwMS, 209 were included, showing 66% experienced non-serious adverse events, while only 4.8% had post-vaccination MS activity, and 14.8% had breakthrough COVID-19 infections.
- Findings revealed that those on fingolimod and anti-CD20 therapies had significantly lower odds of developing specific antibody responses, indicating that these treatments might affect vaccine immunogenicity.
